Skip to content

Vertex Pharmaceuticals VRTX Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin344.7%-0.9pp345.5%-5.4pp351%-1.0pp352%0.0pp
Returns
Return on invested capital71.8%+44.5pp27.3%-91.2pp118.5%-23.9pp142.4%+12.6pp
Efficiency
Asset turnover0.0×-0.1×2.1×-0.3×2.4×0.0×
Liquidity
Current ratio10.4×-0.8×11.2×-5.3×16.5×-2.3×18.8×+0.7×
Leverage
Debt-to-equity0.4×+0.1×0.3×+0.1×0.2×-0.1×0.3×-0.1×
Per Share
Book value per share$269.49+7.0%$251.79+2.5%$245.71+27.8%$192.33+32.6%
Valuation
Market capitalization$455.56B+0.6%$452.7B+23.5%$366.56B+27.8%$286.89B+38.0%
Price / sales39.5×-3.5×43×+4.7×38.3×+4.5×33.8×+3.8×
Price / book26.2×-1.8×28×+5.1×22.9×-0.3×23.2×+1.1×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Vertex Pharmaceuticals's profit margins?
Vertex Pharmaceuticals (VRTX) runs a 86.2% gross margin and a 38.3% operating margin, with a 35.5% net margin.
Where do Vertex Pharmaceuticals's ratios come from?
Every ratio is computed from Vertex Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.